Rare Solid Cancers: An Introduction - Slide 13 - R. Soffietti - Rare CNS cancers
•
0 gostou•302 visualizações
![[object Object],[object Object],[object Object],[object Object],[object Object],RARE SOLID CANCERS: AN INTRODUCTION , Stresa 1/4/2011 Rare CNS Cancers](https://image.slidesharecdn.com/03-soffiettistresa2011-110412084033-phpapp02/85/Rare-Solid-Cancers-An-Introduction-Slide-13-R-Soffietti-Rare-CNS-cancers-1-320.jpg)
![OVERVIEW ON GLIOMAS ,[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recomendados
Recomendados
Mais conteúdo relacionado
Mais procurados
Mais procurados (20)
Destaque
Destaque (9)
Semelhante a Rare Solid Cancers: An Introduction - Slide 13 - R. Soffietti - Rare CNS cancers
Semelhante a Rare Solid Cancers: An Introduction - Slide 13 - R. Soffietti - Rare CNS cancers (20)
Mais de European School of Oncology
Mais de European School of Oncology (20)
Rare Solid Cancers: An Introduction - Slide 13 - R. Soffietti - Rare CNS cancers
- 3. Tabatai et al, Acta Neuropathol 2010, 120(5):585-92
- 4. Sanson et al, JCO 2009, 27(25); 4150-4 IDH 1 IN GLIOBLASTOMAS
- 5. Hartmann et al, Acta Neuropathol (2010) 120:707-718
- 6. Hartmann et al, Acta Neuropathol (2010) 120:707-718
- 7. Van den Bent et al, Clin Cancer Res 16,1597-1604, 2010
- 8. Labussiere et al, Neurology, 74 , 1886 - 2010
- 9. Metellus et al, Acta Neuropathologica 120:719-729, 2010
- 13. Bevacizumab alone or in combination with irinotecan (CPT-11) in recurrent glioblastoma: phase II trial results and comparison with standard treatments OS (weeks) RR (%) PFS (weeks) PFS6 (%) Drug(s) Author 28.4 4.3 6.4 19 CCNU (92) Wick et al, 2010 23 6 9 15 Miscellaneous (225) Wong et al, 1999 30 8 12.4 21 Temozolomide (112) Yung et al, 2000 36 38 22.4 50 BEV+CPT-11 (82) Friedman et al, 2009 25.6 30 10.8 25 BEV (50) Raizer et al, 2010 31 35 16 29 BEV (48) Kreisl et al, 2009 38 28 16.8 42 BEV (85) Friedman et al, 2009
- 14. G.S. (60 yrs), GBM, MGMT-
- 17. Vascular normalization, but GBM cells can migrate far away: a new problem
- 25. Nghiemphu PI, et al. Neurology 2009;72:1217-1222
- 32. International phase III study
- 47. Early versus Delayed Radiotherapy: EORTC 22485 Van den Bent et al , 2005
- 48. Early versus Delayed Radiotherapy: EORTC 22485 Van den Bent et al , 2005
- 58. PCV: Procarbazine, CCNU, Vincristine TMZ: temozolomide *Number of pts with epilepsy not reported Rudà et al, Curr Opin Oncol 2010;22(6):611-20 Seizure response to chemotherapy in low-grade gliomas Author N° pts with seizures/N° of total pts Chemotherapy regimen Seizure response Mason et al,1996 6/9 PCV 100% Soffietti et al, 1998 12/26 PCV 50% Frenay et al, 2005 8/10 PCV 87% Lebrun et al, 2007 22/33 PCV 53%. Pace et al, 2003 31/43 TMZ standard 48% Brada et al, 2003 27/29 TMZ standard 55% Hoang-Xuan et al, 2004 60* TMZ standard Up to 51% Kaloshi et al, 2007 149* TMZ standard Up to 58% Soffietti et al, 2008 (ongoing study) 17/31 TMZ dose-dense 65%
- 62. Temozolomide (TMZ) 1 week on/ 1 week off as initial treatment for progressive low grade oligodendroglial tumors: a phase II AINO (Italian Association for Neuro-Oncology) study. R. Soffietti 1 , R. Rudà 1 , E. Trevisan 1 , E. Laguzzi 1 , D. Guarneri 1 , C. Bomprezzi 2 , M. Caroli 3 1 University of Torino, 2 University of Ancona, 3 University of Milano Italy Proc. ASCO,2019,94s,Chicago 2008
- 67. Preoperative (neoadjuvant) chemotherapy with temozolomide 1week on/1week off followed by radical surgery in patients with low grade gliomas: a pilot study Division of Neuro-Oncology, University of Torino Division of Neurosurgery, University of Milano / Fondazione Policlinico Division of Neuroradiology, University of Milano / S. Raffaele
Notas do Editor
- Do the GBM really suffer from some blood supply deprivation?? -GBM tolerate quite well hypoxia (many HIF inducible genes) GBM cells can migrate far away (gliomatosis) The described angiogenesis-independent tumor growth and the uncoupling of invasion and angiogenesis, represented by the stemlike cancer cells and the cells derived from them, respectively, point at two completely independent mechanisms that drive tumor progression. An alternative mechanism for obtaining essential nutrients may be that the malignant cells are sustained by the preexisting vasculature of the host tissue, as they invade the surrounding parenchyma. -
- The mathematical decomposition of the diffusion tensor into its isotropic (p) and anisotropic (q) components allows to determine tissue diffusion 'signatures', that demonstrate different aspects of tumour behaviour. These maps allow better describe diffusion characteristics at the level of tumor core and peritumoral white matter. By extracting and quantifying the information in the diffusion tensor, various isotropic and anisotropic indices can be calculated. From the mathematical decomposition of the diffusion tensor it is possible to obtain two maps: isotropic (p) and anisotropic (q)